Long-term strategy in the management of postmenopausal osteoporosis

Joint Bone Spine

Volumn 74, Issue 6, 2007, Pages 540-543

  Rizzoli, René ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Bisphosphonates; Bone mineral density; Calcium; Fracture; Nutrition; Teriparatide; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

CALCIUM INTAKE; COST; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; HIGH RISK POPULATION; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INCIDENCE; LIFE EXPECTANCY; LONG TERM CARE; MORBIDITY; MORTALITY; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PREVENTIVE HEALTH SERVICE; QUALITY OF LIFE; SAFETY; SHORT SURVEY; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIET THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 36849044128     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.09.003     Document Type: Short Survey

References (13)

1. Kanis J.A., Oden A., Johnell O., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 (2007) 1033-1046
2. Chevalley T., Guilley E., Herrmann F.R., et al. Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40 (2007) 1284-1289
3. Rizzoli R. The role of calcium in the treatment of osteoporosis. In: Marcus R., Feldman D., Nelson D., and Rosen C. (Eds). Osteoporosis. 3rd ed. (2007), Academic Press
4. Boonen S., Lips P., Bouillon R., et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 92 (2007) 1415-1423
5. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., et al. Effect of vitamin D on falls: a meta-analysis. J Am Med Assoc 291 (2004) 1999-2006
6. Rizzoli R., and Bonjour J.P. Dietary protein and bone health. J Bone Miner Res 19 (2004) 527-531
7. Hauselmann H.J., and Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14 (2003) 2-12
8. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
9. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
10. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc 296 (2006) 2927-2938
11. Khosla S. Parathyroid hormone plus alendronate - a combination that does not add up. N Engl J Med 349 (2003) 1277-1279
12. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
13. Seeman E., Vellas B., Benhamou C., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21 (2006) 1113-1120